In September of 2018, the French National Authority for Health (HAS) published an opinion regarding the inclusion of WISE CRT system - an implantable cardiac resynchronization medical device delivering left ventricular (LV) stimulation without the use of a transvenous probe for patients with cardiac resynchronization indication who are non-responders or cannot be treated with a conventional cardiac resynchronization device (epicardial stimulation with probe via the coronary sinus) in a framework of “forfait innovation” program.
On the 16th of February of 2019, the approval for financing of WISE CRT system was released in the Official French Gazette (Journal Officiel de la République Française). This financing is provided for the 48-months period from the date of the enrollment of the first patient with persistent symptomatic heart failure in a clinical trial to assess efficacy and safety of the device as well as the associated procedure despite optimal drug therapy. The obtained package includes the amount of €25,600 and cannot be combined with other benefits. It is fully covered by the compulsory health insurance schemes.
The package will be supported in the following 4 institutions participating in the study:
- CHU Grenoble-Alpes (North Hospital) in La Tronche
- Rennes University Hospital (Pontchailloux)
- La Timone Hospital (AP-HM) in Marseille
- the Pasteur Clinic in Toulouse
See the full information in French here.
Subscribe to our newsletter delivered every second week not to miss important reimbursement information.